Answers are grounded in this paper and cite their sources.
The 12-week GLE/PIB regimen was well-tolerated with high virologic efficacy in patients with cirrhosis, experience of DAA, or HCV genotype 3; tolerability and SVR rate were comparable with those of DAA-naïve, non-cirrhotic, non-genotype 3 patients who underwent 8-week regimen.
No takes yet. Share an insight, caveat, or question.
Toyoda et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: